This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC
Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Pembrolizumab Combo Shows Promise in Elderly Metastatic NSCLC Cohort
Combining pembrolizumab with pemetrexed met the primary end point of objective response rate in a phase 2 trial.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Surgery Trends Towards Improved Outcomes Vs SABR in Elderly NSCLC Group
Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.
Mobocertinib Does Not Improve PFS Vs Chemotherapy in EGFR Exon 20+ NSCLC
Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.